BlackRock
CTSO icon

BlackRock’s Cytosorbents Corp CTSO Stock Holding History

BlackRock’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$443K Buy
782,992
+12,441
+2% +$8.49K ﹤0.01% 4560
2025
Q4 		$493K Buy
770,551
+5,742
+0.8% +$4.42K ﹤0.01% 4488
2025
Q3 		$714K Buy
764,809
+19,196
+3% +$18.9K ﹤0.01% 4381
2025
Q2 		$954K Buy
745,613
+118,308
+19% +$119K ﹤0.01% 4266
2025
Q1 		$627K Hold
627,305
– – ﹤0.01% 4330
2024
Q4 		$571K Hold
627,305
– – ﹤0.01% 4375
2024
Q3 		$941K Sell
627,305
-28,500
-4% -$31.3K ﹤0.01% 4189
2024
Q2 		$461K Sell
655,805
-66,630
-9% -$57.8K ﹤0.01% 4366
2024
Q1 		$686K Sell
722,435
-3,885
-0.5% -$3.78K ﹤0.01% 4297
2023
Q4 		$806K Sell
726,320
-444
-0.1% -$659 ﹤0.01% 4312
2023
Q3 		$1.37M Sell
726,764
-33,247
-4% -$95.4K ﹤0.01% 4136
2023
Q2 		$2.73M Buy
760,011
+15,107
+2% +$47.8K ﹤0.01% 3927
2023
Q1 		$2.51M Buy
744,904
+2,847
+0.4% +$8.54K ﹤0.01% 3945
2022
Q4 		$1.15M Buy
742,057
+686
+0.1% +$1.02K ﹤0.01% 4367
2022
Q3 		$1.01M Sell
741,371
-3,587
-0.5% -$7K ﹤0.01% 4477
2022
Q2 		$1.63M Sell
744,958
-1,855,479
-71% -$4.26M ﹤0.01% 4336
2022
Q1 		$8.29M Sell
2,600,437
-30,773
-1% -$110K ﹤0.01% 3678
2021
Q4 		$11M Buy
2,631,210
+72,418
+3% +$406K ﹤0.01% 3616
2021
Q3 		$20.8M Sell
2,558,792
-82,374
-3% -$669K ﹤0.01% 3247
2021
Q2 		$19.9M Sell
2,641,166
-187,436
-7% -$1.58M ﹤0.01% 3309
2021
Q1 		$24.6M Buy
2,828,602
+66,314
+2% +$632K ﹤0.01% 3073
2020
Q4 		$22M Buy
2,762,288
+68,756
+3% +$575K ﹤0.01% 2950
2020
Q3 		$21.5M Buy
2,693,532
+407,749
+18% +$3.68M ﹤0.01% 2819
2020
Q2 		$22.6M Buy
2,285,783
+189,135
+9% +$1.74M ﹤0.01% 2732
2020
Q1 		$16.2M Buy
2,096,648
+37,046
+2% +$187K ﹤0.01% 2717
2019
Q4 		$7.93M Sell
2,059,602
-577
-0% -$2.52K ﹤0.01% 3352
2019
Q3 		$10.4M Buy
2,060,179
+52,056
+3% +$303K ﹤0.01% 3191
2019
Q2 		$13.3M Buy
2,008,123
+21,791
+1% +$150K ﹤0.01% 3075
2019
Q1 		$15M Buy
1,986,332
+692
+0% +$5.39K ﹤0.01% 2900
2018
Q4 		$16M Buy
1,985,640
+23,891
+1% +$237K ﹤0.01% 2840
2018
Q3 		$25.3M Buy
1,961,749
+254,902
+15% +$3.2M ﹤0.01% 2738
2018
Q2 		$19.5M Buy
1,706,847
+1,571,041
+1,157% +$14.9M ﹤0.01% 2880
2018
Q1 		$958K Sell
135,806
-4,331
-3% -$32.7K ﹤0.01% 3891
2017
Q4 		$911K Buy
140,137
+3,320
+2% +$21.1K ﹤0.01% 3920
2017
Q3 		$848K Buy
136,817
+24,643
+22% +$126K ﹤0.01% 3957
2017
Q2 		$483K Sell
112,174
-6,999
-6% -$30.7K ﹤0.01% 4031
2017
Q1 		$536K Buy
119,173
+118,773
+29,693% +$664K ﹤0.01% 3945
2016
Q4 		$2K Hold
400
– – ﹤0.01% 3628
2016
Q3 		$3K Buy
+400
New +$2.08K ﹤0.01% 3546

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

BlackRock's CTSO Position: Q1 2026 in Review

BlackRock increased its Cytosorbents Corp (CTSO) stake by 1.6% in Q1 2026, buying an estimated $8.49K and bringing the position to 782,992 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #4560.

BlackRock first reported a position in CTSO in Q3 2016 and has held it in 39 quarters since. The position peaked at $25.3M in Q3 2018. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • BlackRock held 782,992 shares of Cytosorbents Corp worth $443K as of Q1 2026.
  • BlackRock bought 12,441 Cytosorbents Corp shares in Q1 2026, an estimated $8.49K.
  • Cytosorbents Corp made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4560 holding.
  • BlackRock first reported a position in Cytosorbents Corp in Q3 2016 and has held it in 39 quarters since.
  • BlackRock's Cytosorbents Corp position peaked at $25.3M in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.